Gut Microbiota and Immunity
Avenir Team Inserm U1057 / UMR 7203
The gastro-intestinal tract is a complex milieu in which coexist host epithelial and immune cells, a wide array of microorganisms and food antigens. The intestinal microbiota is notably composed of trillions of bacteria, which are strikingly well tolerated by the host, whereas pathogenic microorganisms are recognized and eradicated by the immune system. The mechanisms involved in the distinction between harmful and symbiotic microorganisms remain unclear. In some circumstances, the tolerance toward the intestinal microbiota is broken, leading to inappropriate immune response and intestinal or extra-intestinal inflammation. This is the case in inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) and ulcerative colitis, but possibly also in extra intestinal immune mediated diseases such as rheumatoid arthritis, multiple sclerosis or type1 diabetes. CD and UC are characterized by chronic and relapsing inflammation of the gastrointestinal tract. Their socio-economic issues are important because they affect young subjects and their incidence and prevalence are relatively high in industrialized countries. The exact pathogenesis of CD and UC are still unknown but involves a dysregulated immune response toward the gut microbiota in genetically predisposed host. In IBD a deviation of the gut microbiota composition called dysbiosis has been repeatedly pointed out. Concomitantly, genetic studies, and notably genome wide association studies, have identified several susceptibility loci in genes involved in the interaction with microorganisms.
The aim of the lab is to decipher the mechanisms involved in the complex cross-talk between the gut microbiota and the host in health, and its alterations leading to human diseases such as IBD.
Fields of interest
Contact infoAddress: INSERM U1157 / UMR CNRS 7203, Faculté de Médecine Saint Antoine, 27 rue de Chaligny
Postal code: 75012
Telephone: +33 1 40 01 13 23
Fax: +33 1 40 01 13 90
- Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L
Fungal microbiota dysbiosis in IBD
Gut 2016, pii:gutjnl-2015-310746
- Sokol H, Conway KL, Zhang M, Choi M, Morin B, Cao Z, Villablanca EJ, Li C, Wijmenga C, Yun SH, Shi HN, Xavier RJ.
Card9 Mediates Intestinal Epithelial Cell Restitution, T-helper 17 Responses, and Control of Bacterial Infection in Mice.
Gastroenterology. 2013 Sep;145(3):591-601
- Morgan XC*, Tickle TL*, Sokol H* Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, Leleiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C.
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.
Genome Biol. 2012 Apr 16;13(9):R79.
- Sokol H, Seksik P.
The intestinal microbiota in inflammatory bowel diseases: time to connect with the host.
Curr Opin Gastroenterol. 2010 Jul;26(4):327-31.
- Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J.
Low counts of Faecalibacterium prausnitzii in colitis microbiota.
Inflamm Bowel Dis 2009; 15(8):1183-9.
- Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán L G, Gratadoux J J, Blugeon S, Bridonneau C, Furet J P, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière H. M, Doré J, Marteau P, Seksik P, Langella P.
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6.